Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04901195 · ClinicalTrials.gov registry record · Phase 3
A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
A Phase 3 study of Hidradenitis Suppurativa, sponsored by UCB Biopharma SRL.
- Active
- Registry status
- Phase 3
- Development phase
- 658
- Enrollment target
- 20
- Study locations
NCT04901195: Active Phase 3 study of Hidradenitis Suppurativa, sponsored by UCB Biopharma SRL.
NCT04901195 is a Phase 3 study of Hidradenitis Suppurativa that is active but no longer recruiting, run by UCB Biopharma SRL. The registered enrollment target is 658 participants, above the 585-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (12% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04901195, a Phase 3 study of Hidradenitis Suppurativa, is active but no longer recruiting, sponsored by UCB Biopharma SRL.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 658 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Primary Outcome
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.
Conditions Studied
Interventions
- DRUG Bimekizumab
Study Locations (20)
California
- Hs0005 50162 - Fountain Valley
- Hs0005 50161 - Los Angeles
- Hs0005 50220 - San Diego
- Hs0005 50196 - Thousand Oaks
Florida
- Hs0005 50199 - Miami
- Hs0005 50205 - North Miami Beach
- Hs0005 50152 - Orange Park
- Hs0005 50184 - Pembroke Pines
Georgia
- Hs0005 50193 - Sandy Springs
- Hs0005 50280 - Watkinsville
Massachusetts
- Hs0005 50198 - Beverly
- Hs0005 50146 - Boston
Alabama
- Hs0005 50140 - Birmingham
Arizona
- Hs0005 50175 - Phoenix
Indiana
- Hs0005 50234 - Plainfield
Kentucky
- Hs0005 50425 - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 658 participants |
| Start Date | 2021-05-27 |
| Est. Completion | 2026-07-28 |
| Phase | Phase 3 |
What the registry record for NCT04901195 still lists
NCT04901195 is an interventional study that assigns participants to a tested intervention. The registered 658 participants enrollment target is mid-sized for trials with a published cap, above the 585-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (12% higher).
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which Bimekizumab is the first listed.
NCT04901195 names 20 study sites across 12 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT04901195 about?
NCT04901195 is a clinical study titled "A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa". The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
What is the current status of trial NCT04901195?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 658 participants. The study started on 2021-05-27. Estimated completion is 2026-07-28.
What conditions does trial NCT04901195 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT04901195?
The interventions under investigation include: Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT04901195?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04901195 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04901195's enrollment target sits among peer trials
658 8th of 52 higher than 45 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
RECRUITING · Phase 3
-
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07216742 · 659 participants · Phase 3
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
- NCT03671044 · 657 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
- NCT05338697 · 657 participants
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI